Optinose Acquired by Paratek Pharmaceuticals for $330 Million

Optinose ( (OPTN) ) has provided an update.

Optinose, a company involved in the pharmaceutical industry, has undergone significant changes following a merger agreement. On May 21, 2025, Optinose was acquired by Paratek Pharmaceuticals, resulting in the termination of Optinose’s obligations under its Note Purchase Agreement and the delisting of its common stock from Nasdaq. The merger, valued at approximately $330 million, includes contingent value rights for Optinose shareholders based on future sales milestones of their product XHANCE. This acquisition expands Paratek’s portfolio, which now includes Optinose’s XHANCE alongside Paratek’s antibiotic NUZYRA, positioning Paratek as a multi-product specialty therapeutics company.

The most recent analyst rating on (OPTN) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Optinose stock, see the OPTN Stock Forecast page.

Spark’s Take on OPTN Stock

According to Spark, TipRanks’ AI Analyst, OPTN is a Neutral.

Optinose’s overall stock score reflects significant financial challenges despite recent positive technical trends and a promising corporate event. The company’s high leverage, negative equity, and ongoing unprofitability are critical risks. The merger with Paratek may offer strategic opportunities, but a strategic turnaround is necessary to improve financial stability and stock performance.

To see Spark’s full report on OPTN stock, click here.

More about Optinose

Average Trading Volume: 112,637

Technical Sentiment Signal: Sell

Current Market Cap: $98.34M

See more insights into OPTN stock on TipRanks’ Stock Analysis page.